Seres Therapeutics Stock Price Drops Below 50-Day Average

Shares of the biotech company fall amid analyst downgrades

Apr. 11, 2026 at 8:28am

Got story updates? Submit your updates here. ›

A high-contrast, cinematic close-up of complex financial machinery and equipment, representing the institutional forces and infrastructure underlying the stock market's reaction to Seres Therapeutics' performance.The drop in Seres Therapeutics' stock price below a key technical indicator reflects broader investor concerns about the biotech company's near-term outlook.Cambridge Today

Shares of Seres Therapeutics (NASDAQ:MCRB) fell below their 50-day moving average on Friday, with the stock trading as low as $8.27 per share. The drop comes as Wall Street analysts have recently downgraded the stock, with one firm cutting its rating to 'sell' and another reaffirming a 'sell' recommendation.

Why it matters

Seres Therapeutics is a clinical-stage biotech company focused on developing microbiome-based therapies. The drop in its stock price below a key technical indicator like the 50-day moving average could signal broader investor concerns about the company's pipeline and future prospects.

The details

Seres Therapeutics shares closed at $8.32 on Friday, down 4.5% on the day. The stock has a 50-day moving average of $9.70 and a 200-day average of $14.49. Wall Street analysts have recently issued mixed views on the company, with one firm downgrading it to a 'sell' rating and another reaffirming a 'sell' recommendation, even as a third analyst maintained a 'buy' rating and $22 price target.

  • Seres Therapeutics shares crossed below the 50-day moving average during trading on Friday, April 11, 2026.
  • The company reported quarterly earnings on March 12, 2026.

The players

Seres Therapeutics, Inc.

A clinical-stage microbiome therapeutics company focused on developing living microbial therapies to treat serious diseases.

Wall Street Zen

An investment research firm that recently downgraded Seres Therapeutics to a 'sell' rating.

Canaccord Genuity Group

An investment bank that reaffirmed a 'buy' rating and $22 price target on Seres Therapeutics.

Weiss Ratings

An investment research firm that maintained a 'sell (d)' rating on Seres Therapeutics.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Seres Therapeutics' upcoming earnings report and any further analyst commentary on the stock's performance and outlook.

The takeaway

The drop in Seres Therapeutics' stock price below a key technical indicator like the 50-day moving average, coupled with recent analyst downgrades, suggests growing investor concerns about the company's near-term prospects despite its promising microbiome-based drug pipeline.